Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients

Leukemia. 2018 Oct;32(10):2270-2274. doi: 10.1038/s41375-018-0086-0. Epub 2018 Mar 6.
No abstract available

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Core Binding Factor Alpha 2 Subunit / genetics*
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / genetics*
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Neoplasm Recurrence, Local / genetics
  • Neoplasm, Residual / genetics*
  • RUNX1 Translocation Partner 1 Protein / genetics*
  • Young Adult

Substances

  • Core Binding Factor Alpha 2 Subunit
  • RUNX1 Translocation Partner 1 Protein
  • RUNX1 protein, human
  • RUNX1T1 protein, human